Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice close with heavy volume. Back to even on the day. Some profit-taking from yesterday which is totally cool. I should be fun tomorrow and everyday for the near future with a few exceptions.
Is this why we jumped this morning?
How do we get Reditt and Twitter users to jump on CVSI?
There is bar next to reception to encourage employees to work late.
So we were attacked bu shorters again. That SUCKS, but at least there is an explanation.
Here is an observation that you take it for what you think it is worth:
I am following another stock which I do not yet have a position in that also reported yesterday.
ShotSpoter SSTI has a software system that detects gunfire and reports it to police for rapid response. They have a similar system for fires. SSTI quarterly results in some ways closely resembled CVSI.
They posted their first profitable quarter ever at .03 per share profit and are now on pace to have their first profitable year. Yet, their price per share was down about 10 to 15% of this morning.
If you take into account that they only have 11 million shares, their price per share is almost exactly the same as CVSI.
My conclusion is that maybe both companies are currently fairly priced based on the market which is different from a year ago with trade Wars concerns.
I have some of my shares and CVSI as low as a quarter with an average of just over a dollar. I'm confident that as revenues continue to increase at such a high percentage that in the near future we will again see a pop and price similar to what we did a year ago. Just hold tight!
It's great that Zachs has engaged coverage, but that article used a lot of words and said very little while protecting it's own rearend in the process.
In true Price is Right style I will attempt to screw Deetew with a near last minute prediction of $18,320,001.
That is my understanding, that all one time costs for executives were accounted for in the last quarter.
The cover of Newsweek which I just saw at my grocery store is The Ultimate Guide to CBD oils. I can't seem to put the picture in this post from my phone.
That's a fair concern. In the last two days I have seen new CBD displays from competitors at GNC and in all places DSW Shoes.
I reached out to a contact I have at CV Sciences a made them aware with hopes they can get a sales rep to get their products into those stores.
While it is disappointing to see another product on the show, My overall take away is that signs continue to show that CBD is indeed at beginning of a major boom. CVSI is ahead of the curve to take advantage of impending growth with their GRASS certification. There's always going to be competition and in general competition is a good thing.
I'm seeing signs the company is about to do more as an advertisement push.
There is a new educational program director position open which includes going to trade shows and managing radio interviews.
Also, a casting call went out today by San Diego casting director looking for a doctor who uses CBD for their patience. There's a good chance this is for CV Sciences.
NASDAQ highlights CV Sciences in their own positive article about CBD and clinical trials. Is this is a sign uplisting in imminent?
Seminal Clinical Trial in Healthy Adults Demonstrates Promising Preliminary Evidence of PlusCBDâ„¢ Oil in Sleep, Wellness, and Weight-Loss Applications
https://www.nasdaq.com/press-release/seminal-clinical-trial-in-healthy-adults-demonstrates-promising-preliminary-evidence-of-pluscbd-oi-20190617-00786
LAS VEGAS, June 17, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent supplier and manufacturer of hemp CBD products through its industry-dominating brand, PlusCBDâ„¢ Oil, today announced that a controlled clinical study has demonstrated its product can improve sleep, help reduce appetite, and enhance quality of life in humans. The groundbreaking study is the first-ever of its type, proving that high-quality, hemp CBD oil benefits human lives.
Using a randomized, placebo-controlled, double-blind design, 65 overweight but otherwise healthy men and women ingested either one PlusCBDâ„¢ Oil Gold Formula softgel or a placebo containing olive oil every day for six weeks. Subjects followed their normal diet and a routine of low intensity physical activity. After six weeks of supplementation, the study found PlusCBDâ„¢ Oil supplementation can improve self-reported measures of sleep, quality of life and reduce appetite, while demonstrating no adverse effects on standard biomarkers of safety.
The study was conducted by The Center for Applied Health Sciences (CAHS). CAHS is an industry-leading multidisciplinary Contract Research Organization capable of designing and executing phase I-IV clinical trials within the dietary supplement, pharmaceutical, functional food and medical food industries.
"Collectively, these seminal findings in healthy subjects demonstrate that PlusCBDâ„¢ Oil supplementation can improve measures of sleep, reduce appetite, and enhance quality of life," said Hector Lopez, MD, CMO, and co-founder of CAHS. "This study is an important contribution for all stakeholders, as it represents the first randomized clinical trial that we are aware of regarding the safety and efficacy of multi-constituent hemp CBD extract in healthy human subjects, and we hope it will serve as a template for further research into the many potential benefits of this fascinating compound."
The groundbreaking research was presented for the first time on June 15th at the International Society of Sports Nutrition's 16th Annual Conference and Expo in Las Vegas.
"According to the National Institutes of Health, more than one-third of adults report daytime sleepiness so severe that it interferes with work, driving, and social functioning at least a few days each month," said Joseph Dowling, Chief Executive Officer of CV Sciences. "As the industry leader, we are committed to advancing research and education to help more and more consumers realize the many benefits of hemp CBD supplementation."
"The Center for Applied Health Sciences collected additional data during the clinical trial, and we are looking forward to future analyses that explores how hemp CBD can create positive changes in human stress resilience, nervous system function, body composition, inflammation, as well as targeted gene expression," said Douglas MacKay, Senior Vice President of Scientific and Regulatory Affairs for CV Sciences.
A copy of the abstract, titled "Effects of a CBD-containing Supercritical Fluid Extract of Hemp on Markers of Optimal Wellness, Stress Resilience, and Recovery in Healthy Subjects," is available here.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing novel therapeutics utilizing CBD. The Company's PlusCBDâ„¢ Oil is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada.
Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
scott.vanwinkle@icrinc.com
Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com
CV Sciences CEO Joe Dowling talks with Yahoo Finance about the recent news Kroger will join CVS carrying their products. He said to assume they are in discussions with all major retailers and expect more similar announcements this year.
CV Sciences CEO: expect 'more announcements' following partnership with Kroger
https://finance.yahoo.com/video/cv-sciences-ceo-expect-more-190113432.html
THANKS! I'm going to try to make it. Love the venue.
Is there a stock holder meeting coming up soon? If so, does anyone have the details?
Joe Dowling, CEO of CV Sciences, Inc., was featured on TDAmeritrade discussing the company’s expansion into the Food, Drug & Mass Channel & the current research that is being conducted on #hemp CBD.
Dowling discussed the recent positive research on PTSD. "I think the results were very promising" Dowling said. "Again this is just the beginning of the research."
Dowling went on to stress that PTSD is very hard to treat and that opioids are currently the front-line treatment. "If there is alternative to that, and we certainly think CBD can be an alternative, that will be very positive."
Dowling also discussed the addition of CVS as a major distributor who he now considers a partner. He explained the large retailers are starting with topical, but ingestible products are soon.
Click the link below to watch the full interview. #CVSI http://bit.ly/2Vb8D0f
I'm likely going.
Not after you pay commissions both ways.
I have an Ameritrade account for which my CV Sciences stock are in. The point I'm making with regards to UBS and not being able to purchase with that institution is that there are still severe limitations on big money coming in. I'm I assume that up listing to a major exchange would solve that problem, but I'm not positive.
My ROTH is at UBS which still prohibits me from purchasing CVSI. I can purchase canadian-based marijuana stocks, but not U.S.
CBD Cream Commercial: I do some acting, and as an actor I subscribe to websites that have audition information. This morning I saw a post on Now Casting for an audition for a CBD cream commercial. It didn't specify what company it was for, but this is another sign of CBD oils becoming mainstream and the market emerging.
Now Walgreens to carry CBD Oils in 1,500 stores in Select States
https://www.cnbc.com/2019/03/27/walgreens-to-sell-cbd-products-in-some-stores.html
Walgreens will sell CBD creams, patches and sprays in nearly 1,500 stores in select states, the company told CNBC on Wednesday.
The drugstore chain will sell the cannabis-based products in Oregon, Colorado, New Mexico, Kentucky, Tennessee, Vermont, South Carolina, Illinois and Indiana. Walgreens declined to specify which brands it would carry.
"This product offering is in line with our efforts to provide a wider range of accessible health and wellbeing products and services to best meet the needs and preferences of our customers," Walgreens spokesman Brian Faith said in an email to CNBC.
Rival drugstore chain CVS introduced CBD-containing topicals, including creams and salves, to stores in eight states earlier in March. As the non-psychoactive cannabis compound becomes one of the hottest ingredients in consumer products, retailers are carefully evaluating the market.
Consumers are increasingly curious about CBD, which promises to help everything from anxiety to pain even though there is scant evidence backing up these claims. And while CBD derived from hemp is now legal thanks to the farm bill Congress passed late last year, the FDA says companies still can't add CBD to food or sell it as a dietary supplement.
The regulatory uncertainty has left some large companies on the sidelines for now. Selling CBD-infused beauty and skin-care products brings far less risk, making it an obvious first step for retailers.
I stopped by CV Sciences this morning. I wanted to talk to talk to Christopher Moreo, Director of Operational Development, to see if he could confirm CVS. Mr. Moreo was in a meeting and I was unable to talk to him and the friendly gentleman that checked if he was available smiled and said I would need wait for a press release.
What I can report:
The office was as a busy as I ever seen it. There just seemed to be a lot of activity with people going about their work. Around back, I noticed that they now have their own UPS trailer backed up to the warehouse with a large cart under a canopy that has collapsed boxes to ship product out. At least that is my assumption, as there were some assembled boxes that looked ready to be loaded. The warehouse doors were also open and the shelves appeared to be packed.
All of this is just antidotal info, but I was excited about the buzz that I perceived. I spoke to a few employees including what I believe was a warehouse worker, and everyone appeared happy. It truly looks like a great place to work. Many of the staff were in casual clothes. There is an employee entertainment area up front behind the reception that has a bar, fuse ball, a TV, and a dart board.
We are likely up to fifteen minutes behind. The price was $6.19 when I started typing this.
I saw on the Yahoo board a claim CV Sciences products were available through CVS via a third party site. Not sure if that is factual.
I stopped by my CVS and pharmacist confirmed they will have CBD Oils, but did not know when and what brand.
The bigger take away for now is CBD oils are becoming mainstream as I evident of the picture of the huge rotating billboard at a San Diego mall I posted about on Saturday.
Whether it is CVS or another major retailer, CV Sciences distributions capabilities are on the verge of exploding.
This is literally a HUGE SIGN CBD Oils are now mainstream. This is hanging in the center of North County Fair, one of the largest malls in San Diego.
I tried to share the image, but failed. So here is a link to Twitter page where I could post it:
This is literally a HUGE SIGN CBD Oils are now mainstream. The sign is hanging in the center of North County Fair.@CV_Sciences (CVSI) is a San Diego company and the industry leader for CBD Oils. pic.twitter.com/Zpj8y3Om5U
— Dan McLellan (@sandiegosports) March 17, 2019
I see the potential in a couple years of a dividend that pays more than the price I paid for some of my shares.
I drive by CV Sciences regularly. Last week, I noticed the parking lot appeared full and several cars parked on the street in front of the building. If half their building is now sales, we might be in for some pleasant numbers today, or big jump next Qtr.
Something to Consider: CV Sciences presented at a conference today. Perhaps, those at the conference liked what they heard and purchased shares.
In the center of the orgonal side of the building they occuly is a science lab, the acquired the other half of the building to expand sales.
I would think that is what the lab in the center of their offices are for: Resarch, for new products.
Motley Fool - Better Buy: Medical Marijuana vs. CV Sciences
https://www.fool.com/investing/2019/02/10/better-buy-medical-marijuana-vs-cv-sciences.aspx
CVSI - WINS!
Many investors have jumped on the marijuana stock bandwagon. But there's a different form of cannabis that could be an even bigger story right now. The U.S. legalization of hemp, which is cannabis that contains very low levels of psychoactive ingredient THC, has opened the door for a potentially huge hemp-cased cannabidiol (CBD) market.
Two stocks that hope to become big winners in this hemp market are Medical Marijuana (NASDAQOTH:MJNA) and CV Sciences (NASDAQOTH:CVSI). CV Sciences has performed a lot better than Medical Marijuana has, with its share price skyrocketing nearly 600% last year compared with Medical Marijuana's 50% plunge. But which of these stocks is the better pick now?
The case for Medical Marijuana
Medical Marijuana became the first publicly traded cannabis company in the U.S. in 2009. The company's name is a bit of a misnomer since Medical Marijuana doesn't market any products made from marijuana. However, Medical Marijuana has produced and sold hemp-based products for several years.
The company markets a broad lineup of hemp-based CBD products, including dietary supplements, skin care products, and prescription medications. Medical Marijuana also sells hemp-based CBD supplements for pets and hemp animal bedding and litter products through its wholly owned Phyto Animal Health subsidiary.
While Medical Marijuana is based in the U.S., the company targets international markets as well. It operates subsidiaries in Europe, Mexico, and Brazil, where the company became the first to introduce a medical cannabis product, in 2014.
Medical Marijuana also owns significant stakes in several related businesses. It owns 50% of CanChew Biotechnologies, which develops cannabis chewing gum products that target the treatment of pain and other medical disorders. The company has a 33% stake in KannaLife Sciences, which is researching experimental cannabinoid drugs focused primarily on neurological disorders. Medical Marijuana also owns 43% of Axim Biotechnologies, another biotech that's developing cannabinoid drugs.
The company generated more than $50 million in revenue over the last 12 months, with revenue steadily growing throughout 2018. Much of this growth stemmed from sales of Medical Marijuana's Real Scientific Hemp Oil (RSHO) products. The legalization of hemp in the U.S. should open more opportunities for the company's products as hemp-based CBD becomes more mainstream.
The case for CV Sciences
CV Sciences was established in 2012 and has grown rapidly since then. The company now ranks as the No. 2 hemp-based CBD retailer. Its PlusCBD Oil is the best-selling hemp CBD product in the U.S. market.
There are currently over 50 different stock keeping units (SKUs) for CV Sciences' PlusCBD Oil, reflecting the wide variety of formulas and package sizes sold by the company. Well over 2,000 retail stores carry its products on their shelves.
CV Sciences' revenue continues to skyrocket. During the first three quarters of 2018, the company posted record sales of $34 million. That figure reflected a whopping 153% jump over the prior-year period.
Although hemp CBD products for consumers is CV Sciences' primary business, the company also has a division focused on developing cannabinoid drugs. CV Sciences is conducting preclinical testing on lead candidate CVSI-007, a combination of CBD and nicotine intended to help individuals reduce their dependence on smokeless tobacco products.
CV Sciences hopes to win FDA approval for CVSI-007 through the 505(b)(2) regulatory pathway, which provides a faster process than normal drug approvals by using data from an already-approved drug. Two smoking cessation products have received FDA approval, but there aren't any approved drugs for smokeless tobacco use and addiction.
Better buy
The decision between these two hemp stocks is an easy one, in my opinion. CV Sciences is already profitable. Its revenue is growing much faster than Medical Marijuana. I don't think it's surprising at all that CV Sciences stock's performance has trounced Medical Marijuana's stock performance. CV Sciences is the clear winner.
There are risks for CV Sciences, though. It's possible that the hemp CBD market won't take off as much as some expect. The market could also become crowded with multiple players, including some with deeper pockets than CV Sciences has. However, I still view CV Sciences as one of the top ways to profit from U.S. hemp legalization.
This is an excellent interview on The Street of Martin Sumichrist, the CEO of Level Brands. It maybe of a competitor, but it's great press for the sector.
What's next for CBD? @KatherineRooss sat down with the CEO of @LevelBrands_ More on CBD here: https://t.co/DQZv8anHZJ pic.twitter.com/GfgSFSThar
— TheStreet (@TheStreet) January 17, 2019
Happy New Year! The truth is 2018 was very profitable for those that owned stock in CVSI in 2017. I believe we haven't seen anything yet!
I spoke to the company at the end of the summer. I got the indication then they expected it might happen in early fall. I have nothing new, but expectations on the board are it should be soon with the passage of the Farm Bill.
CVSI just nearly doubled in physical office space! I stopped by CVSI this morning and learned that they have indeed acquired the adjoining office space in the building they occupy in San Diego to nearly double in space. Our growing sales team now occupies the new space as of last week. The picture is from outside the building looking in at the sales team working in the new space. The marketing team remains in the original space. This expansion was discussed when I stopped by in late summer.
3.4 MB CVSI .jpg Check Error
My Roth goes to my grandchildren when they turn 55. My children are 4 and 7.
I think there is a good chance was are at about $6.70 by the end of the day which is about where we were the Friday before going to $9.20 and then getting attacked by the bogus shorter Tweet. Soon after finacials, we set a new 52 week high.